To assess efficacy of first line novel antibiotic combination that is Ceftazidime Avibactam with or without Aztreonam in high risk febrile neutropenia
Not Applicable
Completed
- Conditions
- Health Condition 1: D848- Other specified immunodeficiencies
- Registration Number
- CTRI/2021/10/037636
- Lead Sponsor
- I
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 99
Inclusion Criteria
age above 18 years
Undergoing treatment for hematological malignancies or bone marrow failure syndromes or stem cell transplantation
high-risk febrile neutropenia as defined by
Neutropenia-ANC <500/mm3 and expected to fall below 500/mm3 in 48hrs and lasting for >7 days
Fever -single oral temperature of 38.3 ? C (101° F) on one occasion or 38 ? C (100.4 ° F) on at least 2 occasions (1 hour apart)
and/or significant comorbidities
or haemodynamically unstable patients
More than 5 days admission in any healthcare facility
Exclusion Criteria
Age <18 years
Pregnant or lactating women
Patients being treated with palliative intent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Resolution of fever in 72 hoursTimepoint: 72 hours
- Secondary Outcome Measures
Name Time Method Change of antibiotic therapy in 96 hours <br/ ><br>Transfer to ICU <br/ ><br>Survival at 30 daysTimepoint: 96 hours